.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Scientists recently developed the HSA-C3 anticancer agent. This bimetallic-centered therapeutic increases efficacy while minimizing toxicity. The compound utilizes human serum albumin (HSA) to deliver a bi-copper(II)-centered thiocarbohydrazone directly to tumors. Moreover, C3 integration into an HSA complex improves its pharmacodynamic profile significantly.
Researchers optimized thiocarbohydrazone compounds to create C3, which shows remarkable cytotoxicity. They successfully mapped the HSA-C3 complex. The agent binds specifically to Lys-199 and His-242 residues in the HSA IIA subdomain. Consequently, the HSA-C3 anticancer agent achieves a 74.20% tumor inhibition rate in vivo. In comparison, C3 alone inhibits only 48.71% of growth. Furthermore, this delivery system enhances targeting and reduces adverse side effects.
The HSA-C3 complex also modulates the tumor microenvironment through dual immune activation. Specifically, it blocks the PD-1/PD-L1 interaction to prevent immune evasion. Additionally, the compound resets tumor-associated macrophages toward the M1 phenotype. This approach induces apoptosis and empowers the immune system. Therefore, patients may benefit from more effective and safer metal-based therapies.
The HSA-C3 complex improves outcomes by utilizing human serum albumin as a targeted carrier. This increases the drug concentration at the tumor site. It also boosts the inhibition rate to 74.20%.
The HSA-C3 complex activates the immune system by blocking the PD-1/PD-L1 interaction. It also shifts tumor-associated macrophages to the M1 phenotype, promoting an active immune response.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or as a substitute for the professional judgment of a healthcare provider. Refer to the latest local and national guidelines for clinical practice.
References
Li S et al. Developing a Multitargeted Anticancer Bi-Copper(II)-Centered Thiocarbohydrazone Agent Based on Lys-199 and His-242 Residues in the IIA Subdomain of Human Serum Albumin. J Med Chem. 2026 Mar 24. doi: 10.1021/acs.jmedchem.6c00360. PMID: 41876397.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The HSA-C3 complex, a novel bi-copper agent, achieves 74.20% tumor inhibition by targeting human serum albumin and modulating the immune microenvironment....
5 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
Explore real-world data showing how private oncogenetics and molecular tumor boards achieve 3-week consult turnaround, high ctDNA actionability, and vital germline variant detection, enhancing individualized cancer care and familial risk assessment.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
